Moderate aerobic exercise is part of the daily routine for people with many neurological conditions. But not for people with ALS. Now, new clinical trials promise to change that by evaluating specific routines in people with the disease.

IN BRIEF: A new trial asks whether the NeuRX DPS phrenic pacer can delay the need for non-invasive ventilation in people with ALS in France.

Neuralstem’s stem cell transplantation procedure might be safe according phase I results. But toxicities experienced by patients due to anti-rejection drugs raise questions about whether treatments such as these are ready to enter the clinic.

Emerging ALS mitochondrial-targeted medicines such as dexpramipexole are gathering steam. But, these medicines may need to do a lot more than boost energy production to stop the disease.

Changes in chemical modifications of the genome are emerging as important contributors to ALS. Possible cancer medicines are currently being evaluated to reverse some of these changes. But, according to a recent study, reducing DNA methylation may instead be a better way to go.

Scientists suspect that power outages in the motor nerves may contribute to ALS. But the power crews deployed to keep the energy flowing may actually fuel the progression of the disease according to a new study.

Lest the auld year be forgot, ALS Today turns back the clock to toast the achievements and innovations in ALS in 2011 in this interactive timeline.